Wednesday, April 19, 2017 9:45:24 AM
Use of CytoSorb in traumatic amputation of the forearm and severe septic shock
Prof. Heinz Steltzer, Alexander Grieb, Karim Mostafa Anaesthesiology and Intensive Care Medicine, UKH Meidling & Sigmund Freud Private University, Vienna, Austria
Summary:
This case study reports on a 49-year-old patient, who was admitted to the hospital via helicopter transport after a traumatic amputation of his right forearm.
Case presentation
While working on a landfill cleaning surfaces with a high pressure cleaner, the air pressure tube caught his arm and his right forearm was cut off at the elbow joint
The amputate was not damaged macroscopically, however a wide spectrum of various aerobic and anaerobic pathogens was detected in the wound, many of which were multi-resistant. These included, for example, Aeromonas hydrophila, an enterotoxin-producing bacterium which is endemic in the American tropics; Stenotrophomonas maltophilia, a multi-resistant nosocomial pathogen detected in dialysis fluid; and Clostridium subterminale, which has been described in the medical literature only in nine case reports as being pathogenic. This microbiologic diversity was most probably due to the location of the accident being a landfill.
On admission the patient was treated for shock, followed by X-ray examination and immediate replantation (operation time approx. 8 hours)
After successful surgery and a well-perfused transplant, the patient was postoperatively transferred to the intensive care unit intubated, ventilated and catecholamine-dependent (0.41 µg/kg/min with a mean arterial pressure of 65 mm/Hg)
Development of lactic acidosis (3.6 mmol/l)
Sharp increase in inflammation-relevant parameters (leukocytes 18,700/µl, CRP 13.5 mg/dl, IL-6 539 pg/ml)
Initiation of antibiotic therapy with 3g sultamicillin
Administration of hydrocortisone 20 mg/h + 3 Red Packed Blood Cells
Immediate initiation of continuous renal replacement therapy in combination with CytoSorb because of the anticipated risk of a complex infection due to the accident and the location of the accident (landfill)
Treatment
A total of 8 treatments with CytoSorb over 8 days with therapy intervals of 24 hours each were carried out (interrupted by surgical procedures)
CytoSorb was used in combination with CRRT (Multifiltrate, Fresenius Medical Care) in CVVHDF mode
Blood flow: 100 ml/min
Anticoagulation: Citrate
CytoSorb Adsorber position: pre-hemofilter
Measurements
Demand for catecholamines
Inflammatory parameters (CRP, IL-6, leucocytes)
Lactate
Results
Clear improvement in hemodynamics with reduction of catecholamine dosages
Significant reduction of inflammatory parameters, in particular IL-6 decreased from 1804 pg/ml to 20.1 pg/ml with CytoSorb therapy
Declining lactate values during the 8 treatments
Patient Follow-Up
During the course of the following week development of sepsis with multiple organ failure
Infection and necrosis of the amputate followed by removal of the necrotic tissue and ultimately amputation of the forearm
Continuous stabilization and improvement after amputation while still under CytoSorb for two more days
Daily surgical wound care, disinfection, removal of necrotic tissue
18 days after initial admission the patient was transferred to the normal trauma-surgical ward
Eventual adaptation of a robotic prosthesis and complete recovery of the patient
CONCLUSIONS
The early treatment with CytoSorb was accompanied by a relatively modest systemic inflammatory reaction which subsided without major or permanent organ damage, despite the impressive pathogen spectrum and the pronounced local damage
The early and continuous use of the CytoSorb adsorber was easy and safe for the entire staff of the intensive care unit
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM